| Name | Title | Contact Details |
|---|
Vetagro is a company that specializes in feed additive development and production for the animal feed industry. They focus on developing targeted solutions through scientific research, technological development, innovative formulation, and a focus on q...
Commonwealth Biotechnologies is a Richmond, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Enclara Pharmacia is the combination resulting from the August 2014 acquisition of Hospice Pharmacia by Enclara Health. We believe that this marriage creates the only true solution for hospice mail order pharmacy services and augments an already robust PBM local offering for hospices that want a choice in their pharmacy service model. Andy Horowitz, CEO, continues to lead Enclara Pharmacia. Enclara Pharmacia serves over 500 hospice providers and 84,000 hospice patients per day nationwide. Enclara’s mail order model provides comprehensive pharmacy support, delivering medications directly to hospice patients’ homes, with the backup of local pharmacies to serve their same-day and emergency needs. Comprehensive services include pharmacist consultation 24/7, patient Drug Utilization Review (DUR), Conditions of Participation (CoP) reports, formulary management, account management, and online reporting—all bundled into a predictable per diem reimbursement model. Enclara Pharmacia’s PBM Plus offering provides you with abundant choice and access to our powerful local pharmacy network contracting platform. The service is offered at a fee for service (FFS) price, unbundled, allowing you to choose the level of clinical intervention, if any, your hospice requires, and to “pay as you go” as those resources are utilized. The program gives the control back to you, supporting overall cost containment.
RedPath Integrated Pathology, Inc. is a Pittsburgh-based molecular diagnostics laboratory focused on providing novel solutions for clinicians. RedPath’s patented PathFinderTG® platform produces mutational profiles to help physicians resolve complex diagnostic dilemmas in patients who are at risk of cancer. RedPath performs all clinical testing and R&D in its state-of-the-art, CLIA-certified and CAP-accredited laboratory. The PathFinderTG platform is supported by more than 20 years of scientific and clinical research, and studies using it have been published in more than 200 peer-reviewed journals, including The New England Journal of Medicine. Based on the strong clinical data supporting this platform, RedPath has received positive coverage decisions from Medicare and private payers.